Open AccessSPARCL1 suppresses metastasis in prostate cancer
Author(s) -
Xiang Yuzhu,
Qiu Qingchao,
Jiang Ming,
Jin Renjie,
Lehmann Brian D.,
Strand Douglas W.,
Jovanovic Bojana,
DeGraff David J.,
Zheng Yi,
Yousif Dina A.,
Simmons Christine Q.,
Case Thomas C.,
Yi Jia,
Cates Justin M.,
Virostko John,
He Xiusheng,
Jin Xunbo,
Hayward Simon W.,
Matusik Robert J.,
George Alfred L.,
Yi Yajun
Publication year - 2013
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1016/j.molonc.2013.07.008
Subject(s) - prostate cancer , metastasis , cancer research , biology , in vivo , cancer , cell growth , cell culture , prostate , in vitro , cell migration , tumor suppressor gene , pathology , medicine , carcinogenesis , genetics , biochemistry , microbiology and biotechnology
Purpose Metastasis, the main cause of death from cancer, remains poorly understood at the molecular level. Experimental design Based on a pattern of reduced expression in human prostate cancer tissues and tumor cell lines, a candidate suppressor gene (SPARCL1) was identified. We used in vitro approaches to determine whether overexpression of SPARCL1 affects cell growth, migration, and invasiveness. We then employed xenograft mouse models to analyze the impact of SPARCL1 on prostate cancer cell growth and metastasis in vivo. Results SPARCL1 expression did not inhibit tumor cell proliferation in vitro. By contrast, SPARCL1 did suppress tumor cell migration and invasiveness in vitro and tumor metastatic growth in vivo, conferring improved survival in xenograft mouse models. Conclusions We present the first in vivo data suggesting that SPARCL1 suppresses metastasis of prostate cancer.